Drug Guide

Generic Name

Prucalopride Succinate

Brand Names Motegrity

Classification

Therapeutic: Laxative, Prokinetic agent

Pharmacological: Serotonin 5-HT4 receptor agonist

FDA Approved Indications

  • Chronic idiopathic constipation in adults

Mechanism of Action

Prucalopride selectively stimulates 5-HT4 receptors in the gastrointestinal tract, enhancing peristalsis and facilitating bowel movements.

Dosage and Administration

Adult: Typically 2 mg once daily with or without food. Dose may be reduced to 1 mg in cases of renal impairment.

Pediatric: Not approved for pediatric use.

Geriatric: No specific dose adjustment; monitor renal function.

Renal Impairment: Adjust dose based on renal function; generally, 1 mg once daily for moderate impairment, avoid in severe impairment.

Hepatic Impairment: Not specifically studied; use with caution.

Pharmacokinetics

Absorption: Rapidly absorbed after oral administration.

Distribution: Widely distributed; specific volume not well defined.

Metabolism: Primarily metabolized via hepatic pathways; not a significant substrate for CYP450 enzymes.

Excretion: Excreted mainly via urine and feces.

Half Life: Approximately 20–30 hours.

Contraindications

  • Hypersensitivity to prucalopride or any component of the formulation.

Precautions

  • Use cautiously in patients with renal impairment, cardiovascular disease, and history of seizures. Monitor for cardiovascular adverse effects.

Adverse Reactions - Common

  • Nausea (Common)
  • Abdominal pain (Common)

Adverse Reactions - Serious

  • Heart rate increase, arrhythmias (Rare)
  • Seizures (Very rare)

Drug-Drug Interactions

  • Caution with other medications that prolong QT interval.

Drug-Food Interactions

  • No significant interactions reported.

Drug-Herb Interactions

  • Limited data; consult healthcare provider.

Nursing Implications

Assessment: Monitor bowel movement frequency and consistency. Assess for cardiovascular symptoms.

Diagnoses:

  • Risk for constipation or bowel obstruction.
  • Risk for cardiac arrhythmias.

Implementation: Administer as prescribed. Educate patient on response and side effects.

Evaluation: Effectiveness in relieving constipation; monitor for adverse cardiac and neurological events.

Patient/Family Teaching

  • Take medication exactly as prescribed.
  • Report any palpitations, dizziness, or seizures to healthcare provider.
  • Maintain hydration and diet high in fiber.
  • Do not crush or split tablets.

Special Considerations

Black Box Warnings:

  • Potential increased risk of cardiovascular events, especially in patients with pre-existing heart conditions.

Genetic Factors: Limited pharmacogenetic data.

Lab Test Interference: No known interference.

Overdose Management

Signs/Symptoms: Nausea, vomiting, dizziness, arrhythmias, seizures.

Treatment: Supportive care; activated charcoal if within hour of ingestion; cardiovascular monitoring; seizure management as needed.

Storage and Handling

Storage: Store at room temperature away from moisture and heat.

Stability: Stable up to the expiration date on the package.

This guide is for educational purposes only and is not intended for clinical use.